The WOMAN trial (2017) established the benefit of tranexamic acid in postpartum haemorrhage. What was its primary finding regarding mortality?

• A Tranexamic acid reduced all-cause maternal mortality by 31%
• B Tranexamic acid reduced hysterectomy rates but not mortality
• C Benefit was only seen in caesarean section deliveries
• D Tranexamic acid significantly reduced death due to bleeding when given within 3 hours of delivery ✓

Explanation

The WOMAN trial (Lancet 2017) demonstrated that tranexamic acid reduced death from bleeding in PPH by 19% overall, with the benefit being greatest when given within 3 hours of delivery. The effect on all-cause mortality was not statistically significant, but there was a clear reduction in bleeding-related deaths. This trial established early tranexamic acid administration as standard of care in PPH.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.